First Tracks Biotherapeutics (NASDAQ:TRAX) Price Target Raised to $60.00

First Tracks Biotherapeutics (NASDAQ:TRAX) had its price target upped by Wedbush from $30.00 to $60.00 in a research note issued to investors on Tuesday, Marketbeat.com reports. Wedbush currently has an outperform rating on the stock.

Several other equities research analysts also recently issued reports on the stock. HC Wainwright raised their price objective on shares of First Tracks Biotherapeutics from $30.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. UBS Group initiated coverage on First Tracks Biotherapeutics in a research report on Tuesday, April 21st. They issued a “buy” rating and a $45.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on First Tracks Biotherapeutics in a research note on Thursday, April 23rd. They set an “overweight” rating and a $31.00 target price on the stock. Barclays boosted their price target on First Tracks Biotherapeutics from $40.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Finally, Wells Fargo & Company increased their price objective on First Tracks Biotherapeutics from $30.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, First Tracks Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $47.88.

First Tracks Biotherapeutics Stock Up 14.1%

Shares of TRAX stock opened at $47.78 on Tuesday. The company has a market cap of $1.67 billion and a P/E ratio of -25.97. The business’s 50-day moving average is $24.01. First Tracks Biotherapeutics has a 52 week low of $14.72 and a 52 week high of $48.00.